These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 18406993

  • 1. New anticoagulant agents: direct thrombin inhibitors.
    Nutescu EA, Shapiro NL, Chevalier A.
    Cardiol Clin; 2008 May; 26(2):169-87, v-vi. PubMed ID: 18406993
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro.
    Nielsen VG, Steenwyk BL, Gurley WQ, Pereira SJ, Lell WA, Kirklin JK.
    J Heart Lung Transplant; 2006 Jun; 25(6):653-63. PubMed ID: 16730571
    [Abstract] [Full Text] [Related]

  • 4. Direct thrombin inhibitors.
    Lee CJ, Ansell JE.
    Br J Clin Pharmacol; 2011 Oct; 72(4):581-92. PubMed ID: 21241354
    [Abstract] [Full Text] [Related]

  • 5. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
    Elg M, Gustafsson D, Deinum J.
    Thromb Haemost; 1997 Oct; 78(4):1286-92. PubMed ID: 9364999
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Dabigatran etexilate: a possible replacement for heparinoids and vitamin K antagonists?
    Guay DR.
    Hosp Pract (1995); 2011 Feb; 39(1):105-25. PubMed ID: 21441766
    [Abstract] [Full Text] [Related]

  • 8. Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation.
    Young G, Yonekawa KE, Nakagawa PA, Blain RC, Lovejoy AE, Nugent DJ.
    Blood Coagul Fibrinolysis; 2007 Mar; 18(2):97-103. PubMed ID: 17287624
    [Abstract] [Full Text] [Related]

  • 9. Direct thrombin inhibition with bivalirudin as an antithrombotic strategy in general and interventional cardiology.
    Ahrens I, Smith BK, Bode C, Peter K.
    Expert Opin Drug Metab Toxicol; 2007 Aug; 3(4):609-20. PubMed ID: 17696810
    [Abstract] [Full Text] [Related]

  • 10. Dabigatran etexilate: future directions in anticoagulant treatment.
    Schulman S, Reilly PA.
    Clin Appl Thromb Hemost; 2009 Aug; 15 Suppl 1():32S-41S. PubMed ID: 19679590
    [Abstract] [Full Text] [Related]

  • 11. Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.
    Siddiqui FM, Qureshi AI.
    Expert Opin Pharmacother; 2010 Jun; 11(8):1403-11. PubMed ID: 20446854
    [Abstract] [Full Text] [Related]

  • 12. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.
    Stangier J, Clemens A.
    Clin Appl Thromb Hemost; 2009 Jun; 15 Suppl 1():9S-16S. PubMed ID: 19696042
    [Abstract] [Full Text] [Related]

  • 13. First oral thrombin inhibitor enters market: drug does not require clinicians to monitor INR.
    Thompson CA.
    Am J Health Syst Pharm; 2010 Dec 01; 67(23):1974, 1976. PubMed ID: 21098360
    [No Abstract] [Full Text] [Related]

  • 14. Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: which assay is helpful?
    Curvers J, van de Kerkhof D, Stroobants AK, van den Dool EJ, Scharnhorst V.
    Am J Clin Pathol; 2012 Oct 01; 138(4):551-8. PubMed ID: 23010710
    [Abstract] [Full Text] [Related]

  • 15. [Direct inhibitors of thrombin, hirudin, bivalirudin, and dabigatran etexilate].
    Meddahi S, Samama MM.
    J Mal Vasc; 2011 Feb 01; 36(1):24-32. PubMed ID: 21239127
    [Abstract] [Full Text] [Related]

  • 16. Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy.
    Avecilla ST, Ferrell C, Chandler WL, Reyes M.
    Am J Clin Pathol; 2012 Apr 01; 137(4):572-4. PubMed ID: 22431533
    [Abstract] [Full Text] [Related]

  • 17. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY, Larsen TB, Skjøth F, Rasmussen LH.
    J Am Coll Cardiol; 2012 Aug 21; 60(8):738-46. PubMed ID: 22575324
    [Abstract] [Full Text] [Related]

  • 18. Laboratory Monitoring of Parenteral Direct Thrombin Inhibitors.
    Van Cott EM, Roberts AJ, Dager WE.
    Semin Thromb Hemost; 2017 Apr 21; 43(3):270-276. PubMed ID: 28052306
    [Abstract] [Full Text] [Related]

  • 19. Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors.
    Lepor NE.
    Rev Cardiovasc Med; 2007 Apr 21; 8 Suppl 3():S9-17. PubMed ID: 17917621
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.